Dimethylphenylpiperazinium
Dimethylphenylpiperazinium (DMPP) is a nicotinic acetylcholine receptor agonist which is selective for the ganglionic subtype.[1] One of the earliest reports on the pharmacology of DMPP, describing it as a ganglion-stimulating, hypertensive agent, came from Graham Chen and his co-workers at Parke, Davis & Co.[2]
![]() | |
| Identifiers | |
|---|---|
IUPAC name
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H19N2 |
| Molar mass | 191.29 g/mol g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| | |
See also
- Phenylpiperazine
References
- Prado WA, Segalla DK (August 2004). "Antinociceptive effects of bethanechol or dimethylphenylpiperazinium in models of phasic or incisional pain in rats". Brain Res. 1018 (2): 272–82. doi:10.1016/j.brainres.2004.05.085. PMID 15276888.
- G. Chen, R. Portman and A. Wickel (1951) J. Pharmacol. Exp. Ther. 103 (1951).
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.
